Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moderate hepatic impairment (HI) on lemborexant pharmacokinetics and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacol Res Perspect
Asıl Yazarlar: Dayal, Satish, Aluri, Jagadeesh, Hall, Nancy, Filippov, Gleb, Moline, Margaret, Reyderman, Larisa, Landry, Ishani
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2021
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8023329/
https://ncbi.nlm.nih.gov/pubmed/33822479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.758
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller